Get startedLog in
    Picture of Incyte logo

    INCY — Incyte News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareBalancedLarge CapHigh Flyer
    All News

    Brief: Incyte Says Frontmind Trial Shows 25% Reduction In Disease Progression Or Death In High-Risk Dlbcl

    Picture of Incyte logoIncyte
    30/05/2026 13:13
    BRIEF-Incyte Says Frontmind Trial Shows 25% Reduction In Disease Progression Or Death In High-Risk Dlbcl
    May 30 (Reuters) - Incyte Corp INCY.O:
    • INCYTE - FRONTMIND TRIAL SHOWS 25% REDUCTION IN DISEASE PROGRESSION OR DEATH IN HIGH-RISK DLBCL
    • INCYTE: PIVOTAL FRONTMIND TRIAL SHOWED TAFASITAMAB (MONJUVI®/MINJUVI®) COMBINATION SIGNIFICANTLY PROLONGED PROGRESSION-FREE SURVIVAL
    Source text: ID:nBw64pQHRa
    Further company coverage: INCY.O

     ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Incyte

    See all news